What is klebsiella pneumoniae

Bacterial Characteristics

Klebsiella pneumoniae is a gram-negative, facultative anaerobic bacterium belonging to the Enterobacteriaceae family. It is rod-shaped and surrounded by a thick mucopolysaccharide capsule that gives it a characteristic mucoid appearance. This capsule is a major virulence factor, helping the bacterium resist phagocytosis and antibiotics while facilitating adhesion to host tissues.

Natural Habitat and Transmission

Klebsiella pneumoniae is part of the normal flora of the human digestive tract, respiratory tract, and skin. However, it becomes pathogenic when it spreads to normally sterile body sites. Transmission primarily occurs through direct contact, contaminated surfaces, or aspiration of respiratory secretions. Healthcare settings pose higher transmission risks due to concentrated populations of vulnerable patients and frequent antibiotic exposure.

Clinical Infections

The bacterium causes a wide range of infections including pneumonia (particularly in individuals with chronic lung disease), urinary tract infections (UTIs), wound infections, bloodstream infections, and liver abscesses. In hospitalized patients, Klebsiella pneumoniae is among the leading causes of nosocomial infections. Symptoms vary depending on infection site but may include fever, cough, dysuria, or septic shock in severe cases.

Antibiotic Resistance

A major concern in modern medicine is the emergence of antibiotic-resistant strains, particularly carbapenem-resistant Klebsiella pneumoniae (CRKP). These multidrug-resistant organisms limit treatment options and increase mortality rates. Resistance mechanisms include production of carbapenemases (enzymes that destroy carbapenem antibiotics) and other beta-lactamases. The World Health Organization lists resistant Klebsiella as a critical priority pathogen.

Clinical Management

Treatment depends on infection severity and antibiotic susceptibility patterns. Empiric therapy typically involves broad-spectrum antibiotics such as carbapenems or fluoroquinolones. For resistant strains, combination therapy with agents like colistin or polymyxin B may be necessary. Prevention focuses on infection control measures, judicious antibiotic use, and early identification of resistant strains through surveillance programs.